Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter
Authors:
- Peter E. PolakPPPeter E. Polak
- Arnoud Van'T HofAHArnoud Van'T Hof
- Henrik S. RasmussenHRHenrik S. Rasmussen
- Peter H. DunselmanPDPeter H. Dunselman
- J.HErre KingmaJKJ.HErre Kingma
- 1 February 1992
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 69 (4) , 417-419
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- A dose‐ranging study of UK‐68,798, a novel class III anti‐arrhythmic agent, in normal volunteers.British Journal of Clinical Pharmacology, 1991
- Pharmacokinetic and pharmacodynamic effects of UK‐68,798, a new potential class III antiarrhythmic drug.British Journal of Clinical Pharmacology, 1991
- The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythmJACC, 1990
- Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimensEuropean Heart Journal, 1988
- Sotalol: A beta blocker with unique antiarrhythmic propertiesAmerican Heart Journal, 1987
- Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle.Circulation Research, 1977